Helicobacter pylori
Conditions
Interventions
group VB :Vonolasone fumarate (Walker) 20mg, bid+ Amoxicillin 750mg, qid+ Bifidobacterium Tetravaccine Tablets 3 tablets, tid
group VP :Vonolasone fumarate (Walker) 20mg, bid+ Amoxicillin 750mg, qid+ Bifidobacterium Tetravaccine Tablets Placebo 3 tablets, tid
Sponsors
Department of Gastroenterology, Nanjing First Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Aged between 18 and 65 years; No gender limit; 2. Patients who are diagnosed with Helicobacter pylori; 3. Patients who have not received Helicobacter pylori eradication treatment in the past, or who have failed to eradicate in the early stage but have not received eradication treatment within half a year; 4. Voluntarily participate in this experiment and sign informed consent.
Exclusion criteria
Exclusion criteria: 1. Allergic to the study drug (penicillin allergy, etc.); 2. Patients with chronic gastritis accompanied by peptic ulcer; 3. Patients who have received Helicobacter pylori eradication treatment within six months; 4. Antibiotics, bismuth and probiotics were used 4 weeks before treatment, and histamine H2 receptor antagonists, PPI or potassium competitive acid blockers were used 2 weeks before treatment; 5. Use adrenocorticosteroids, non-steroidal anti-inflammatory drugs or anticoagulants; 6. History of esophageal or gastric surgery; 7. Pregnant and lactating patients; 8. Suffering from serious concomitant diseases, such as liver disease, cardiovascular disease, lung disease, kidney disease, tumor; 9. Drink too much.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| H.pylori eradication rate;Adverse reaction assessment; | — |
Countries
China
Contacts
Public ContactZhang Zhenyu
Outcome results
None listed